819869-77-7

Basic information

• Product Name: DOTA-mono-NHS-tris(t-Bu ester)(B-270)
• Synonyms: DOTA-mono-NHS-tris(t-Bu ester)(B-270);DOTA-Mono-NHS-tris(t-Bu ester);1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethyl]-, tris(1,1-diMethylethyl) ester;DOTA-tris-tBu-ester NHS;1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 4,7,10-tris(1,1-dimethylethyl) 1-(2,5-dioxo-1-pyrrolidinyl) ester
• CAS NO: 819869-77-7
• Molecular Formula: C₃₂H₅₅N₅O₁₀
• Molecular Weight: 669.8066
• Mol File: 819869-77-7.mol

Chemical Properties

• Boiling Point: 686.8±65.0 °C(Predicted)
• Appearance: /
• Density: 1.21±0.1 g/cm3(Predicted)
• PKA: 5.49±0.20(Predicted)
• CAS DataBase Reference: DOTA-mono-NHS-tris(t-Bu ester)(B-270)(CAS DataBase Reference)
• NIST Chemistry Reference: DOTA-mono-NHS-tris(t-Bu ester)(B-270)(819869-77-7)
• EPA Substance Registry System: DOTA-mono-NHS-tris(t-Bu ester)(B-270)(819869-77-7)

Safety Data

• Hazardous Substances Data: 819869-77-7(Hazardous Substances Data)

Usage

Uses

Used in Radiopharmaceutical Synthesis:
DOTA-mono-NHS-tris(t-Bu ester)(B-270) is used as a chelating agent for the synthesis of radiopharmaceuticals in the medical industry. It facilitates the attachment of radionuclides to biomolecules, enabling the development of imaging agents and targeted therapies for various diseases.
Used in Drug Delivery Systems:
In the pharmaceutical industry, DOTA-mono-NHS-tris(t-Bu ester)(B-270) is used as a component in drug delivery systems. It aids in the conjugation of therapeutic agents to targeting molecules, enhancing the specificity and efficiency of drug delivery to desired sites within the body.
Used in Diagnostic Assays:
DOTA-mono-NHS-tris(t-Bu ester)(B-270) is utilized as a reagent in the development of diagnostic assays. Its ability to bind with various biomolecules allows for the creation of sensitive and specific tests for detecting diseases or monitoring biological processes.
Used in Protein Interaction Studies:
In the field of biochemistry, DOTA-mono-NHS-tris(t-Bu ester)(B-270) is used as a research tool for studying protein interactions. Its reactive NHS ester group allows for the covalent attachment of proteins to other molecules or surfaces, providing insights into protein function and interactions.
Used in Biomolecule Conjugation:
DOTA-mono-NHS-tris(t-Bu ester)(B-270) is employed as a conjugation reagent across various scientific disciplines. Its reactive group enables the attachment of biomolecules to different substrates, such as nanoparticles or solid supports, for applications in biosensing, immunoassays, and other bioanalytical techniques.

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 192635-89-5 phenylmethyl 2-(1,4,7,10-Tetraaza-4,7,10-tris(((tert-butyl)oxycarbonyl)methyl)cyclododecyl)-acetate 
• 294-90-6 1,4,7,10-tetraazacyclododecan 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 60239-18-1 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane 
• 122555-91-3 1,4,7-tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane 
• 825625-07-8 tri-tert-butyl 2,2’,2’‘-(10-(2-ethoxy-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate 
• 137076-54-1 1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane-10-acetic acid 

Downstream Products

• 170908-81-3 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(N-hydroxysuccinimidyl ester) 

Relevant articles and documents

RGD-cyclam conjugate: Synthesis and potential application for positron emission tomography

Cyclam and DOTA-containing positron emission tomography radiotracers were prepared by using a modular chemical strategy based on peptide synthesis and chemoselective ligations. These molecules encompass two functional domains, one a tumour 'homing' domain and the other a chelating ligand for copper allowing nuclear imaging of tumours.

A bimodal MRI and NIR liposome nanoprobe for tumor targeted molecular imaging

The combination of complementary MRI and NIR imaging methods evolved to provide an even more powerful bioimaging tool. Herein, a novel bimodal MRI/NIR nanoprobe GCF-HDA was prepared via a facile self-assembly approach of three types of amphiphilic structures in aqueous solution. The Stokes shift of the NIR moiety increased from 30 to 150 nm and fluorescence quantum yield increased from 1.5 to 8% after conjugation with electron-rich hexadecylamine (HDA) to organic dye Cy7. The photostability of the nanoprobe GCF-HDA was dramatically improved after involving the newly synthesized dye. Molecular dynamics simulation demonstrated that the GCF-HDA is composed of 2.0-3.5 nm clusters and in each cluster the head groups of the amphiphilic molecules assemble together and the tail groups point outwards. The r1 and r2 relaxivities of GCF-HDA were found to be 11.87 and 19.91 mM-1 s-1 per Gd(iii) chelate at 0.5 T, respectively. In vitro cellular imaging with human glioma U-87 MG cells showed that the GCF-HDA was able to enter the cells and accumulate in the cytoplasm. The targeted GCF-HDA resulted in higher MR contrast enhancement and stronger fluorescence intensity than the corresponding non-targeted probe GC-HDA in the tumor tissue 96 hours post injection. Ex vivo fluorescence imaging and histological analysis of the tumor tissue further confirmed the specific binding ability of the GCF-HDA.

Conjugates of the B-subunit of shiga toxin for use as contrasting agents for imaging and therapy

Multivalent conjugates comprising the following formula: (STxB-linker A-S)x-GNS-(S-linker B-T)y wherein STxB is the B-subunit of Shiga toxin; linker A is a noncleavable linker; linker B is a cleavable linker used to release at least

CONJUGATES OF THE B-SUBUNIT OF SHIGA TOXIN FOR USE AS CONTRASTING AGENTS FOR IMAGING AND THERAPY

Multivalent conjugates comprising the following formula: (STxB-linker A-S)x-GNS-(S-linker B-T)y wherein STxB is the B-subunit of Shiga toxin; linker A is a noncleavable linker; linker B is a cleavable linker used to release at least

LDL-based nanoparticles for contrast enhanced MRI of atheroplaques in mouse models

A LDL particle functionalized with a GdDO3A-monoamide chelate with a long alkenyl anchor (GdDO3A-OA) was prepared for in vivo detection of atheroplaques. The GdDO3A-OA, when successfully intercalated into the lipid layer of LDL particles, led to a signifi

CASCADE MACROMOLECULAR CONTRAST AGENTS FOR MEDICAL IMAGING

The present invention provides macromolecular contrast media for diagnostic imaging modalities.

Multimodal image-guided enzyme/prodrug cancer therapy

The conjugate of bacterial cytosine deaminase (bCD) and poly-l-lysine (PLL) that was functionalized with biotin, rhodamine, and Gd3+-DOTA was synthesized and characterized. It demonstrated high relaxivity, improved enzymatic specificity to prodrug 5-fluorocytosine, low cytotoxicity, efficient cell uptake, and high enzymatic stability in fresh mouse serum and human breast cancer cell culture. Copyright

Process for making a chelating agent for labeling biomolecules using preformed active esters

The present invention is directed, in general, to a method for making high yields of functionalized cyclic or acyclic tertiary amine-containing compounds, termed active esters, the functionalized compounds themselves, and diagnostic or therapeutic systems incorporating such compounds. Ester groups are attached to all but one of its Nitrogen atoms of the tertiary amine-containing compound. Therefore, an active agent, in the presence of coupling agent, attaches to the remaining amine via a carboxylate group attached to the amine, to produce high yields of the active ester. The active ester is then combined with a biomolecule, to produce high yields of a bioconjugated product. A metal ion may be chelated to the bioconjugated product to produce a chelating agent for use in either diagnostic or therapeutic applications.